Protagonist Therapeutics (PTGX) Preferred Stock Liabilities (2015 - 2016)

Protagonist Therapeutics has disclosed Preferred Stock Liabilities across 2 years of filings, most recently posting $66.6 million for Q2 2016.

• Preferred Stock Liabilities for Q2 2016 came in at $66.6 million, changed N/A year-over-year; the trailing twelve-month figure through Jun 2016 was $66.6 million (changed N/A YoY), and the FY2015 annual result was $37.0 million, up 79.8% from the prior year.
• Preferred Stock Liabilities came in at $66.6 million for Q2 2016 at Protagonist Therapeutics, up from $37.0 million in the prior quarter.
• In the past five years, Preferred Stock Liabilities ranged from a high of $66.6 million in Q2 2016 to a low of $37.0 million in Q4 2015.